



Clinical trial results:

A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase 3 study to investigate efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care

Summary

EudraCT number	2015-000950-39
Trial protocol	DK SE HU GB AT DE CZ ES FI PT BE BG NL LT PL FR GR RO IE
Global end of trial date	SK IT 02 February 2021

Results information

Result version number	v1
This version publication date	10 February 2022
First version publication date	10 February 2022

Trial information

Trial identification

Sponsor protocol code	BAY94-8862/17530
-----------------------	------------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02545049
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Bayer AG
Sponsor organisation address	Kaiser-Wilhelm-Allee, Leverkusen, Germany, D-51368
Public contact	Therapeutic Area Head, Bayer AG, clinical-trials-contact@bayer.com
Scientific contact	Therapeutic Area Head, Bayer AG, clinical-trials-contact@bayer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	02 February 2021
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	02 February 2021
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

Primary objective was to: - Demonstrate whether, in addition to standard of care, finerenone is superior to placebo in delaying the time to first occurrence of cardiovascular (CV) mortality and morbidity in subjects with type 2 diabetes mellitus (T2D) and the clinical diagnosis of diabetic kidney disease (DKD).

Protection of trial subjects:

The conduct of this clinical study met all local legal and regulatory requirements. The study was conducted in accordance with ethical principles that have their origin in the Declaration of Helsinki and the International Council for Harmonization guideline E6: Good Clinical Practice. Before entering the study, the informed consent was read by and explained to all the subjects. Participating subjects signed informed consent form and could withdraw from the study at any time without any disadvantage and without having to provide a reason for this decision. Only investigators qualified by training and experience were selected as appropriate experts to investigate the study drug.

Background therapy:

Standard of care: individual maximum tolerated labeled dose of either an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB) but not both.

Evidence for comparator: -

Actual start date of recruitment	17 September 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Austria: 95
Country: Number of subjects enrolled	Belgium: 78
Country: Number of subjects enrolled	Bulgaria: 625
Country: Number of subjects enrolled	Switzerland: 26
Country: Number of subjects enrolled	Czechia: 163
Country: Number of subjects enrolled	Germany: 131
Country: Number of subjects enrolled	Denmark: 162
Country: Number of subjects enrolled	Spain: 258
Country: Number of subjects enrolled	Finland: 104
Country: Number of subjects enrolled	France: 47
Country: Number of subjects enrolled	United Kingdom: 67
Country: Number of subjects enrolled	Greece: 29
Country: Number of subjects enrolled	Hungary: 215
Country: Number of subjects enrolled	Ireland: 4
Country: Number of subjects enrolled	Italy: 241

Country: Number of subjects enrolled	Lithuania: 25
Country: Number of subjects enrolled	Netherlands: 74
Country: Number of subjects enrolled	Norway: 38
Country: Number of subjects enrolled	Poland: 145
Country: Number of subjects enrolled	Portugal: 80
Country: Number of subjects enrolled	Romania: 111
Country: Number of subjects enrolled	Russian Federation: 390
Country: Number of subjects enrolled	Slovakia: 37
Country: Number of subjects enrolled	Sweden: 80
Country: Number of subjects enrolled	Turkey: 116
Country: Number of subjects enrolled	Ukraine: 163
Country: Number of subjects enrolled	Canada: 180
Country: Number of subjects enrolled	Puerto Rico: 9
Country: Number of subjects enrolled	United States: 918
Country: Number of subjects enrolled	China: 325
Country: Number of subjects enrolled	Hong Kong: 49
Country: Number of subjects enrolled	Israel: 278
Country: Number of subjects enrolled	Japan: 503
Country: Number of subjects enrolled	Korea, Republic of: 144
Country: Number of subjects enrolled	Malaysia: 64
Country: Number of subjects enrolled	Philippines: 49
Country: Number of subjects enrolled	Singapore: 25
Country: Number of subjects enrolled	Thailand: 40
Country: Number of subjects enrolled	Taiwan: 101
Country: Number of subjects enrolled	Vietnam: 47
Country: Number of subjects enrolled	Argentina: 256
Country: Number of subjects enrolled	Brazil: 210
Country: Number of subjects enrolled	Chile: 72
Country: Number of subjects enrolled	Colombia: 187
Country: Number of subjects enrolled	Mexico: 116
Country: Number of subjects enrolled	Australia: 87
Country: Number of subjects enrolled	New Zealand: 56
Country: Number of subjects enrolled	South Africa: 132
Worldwide total number of subjects	7352
EEA total number of subjects	2742

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	3510
From 65 to 84 years	3783
85 years and over	59

Subject disposition

Recruitment

Recruitment details:

Study was conducted at multiple centers in 48 countries/regions between 17-Sep-2015 (first subject first visit) and 02-Feb-2021 (last subject last visit).

Pre-assignment

Screening details:

Overall, 19381 subjects were screened. Of them, 11944 subjects were screening failures and 7437 subjects were randomized. 85 subjects were prospectively excluded from the analyses due to critical GCP violations resulting in 7352 in full analysis set. 7341 subjects received study treatment. 1 subject was assigned to placebo but received finerenone.

Period 1

Period 1 title	Analyzed (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Finerenone

Arm description:

Subjects received finerenone 10 mg or 20 mg once daily in addition to standard of care therapy

Arm type	Experimental
Investigational medicinal product name	Finerenone
Investigational medicinal product code	BAY94-8862
Other name	Kerendia
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Oral tablet; starting dose at 10 mg for subjects with an eGFR between 25 to < 60 mL/min/1.73m² at the Screening Visit; starting dose at 20 mg for subjects with an eGFR ≥ 60 mL/min/1.73m² at the Screening Visit; dose could be up-titrated from Month 1 onwards or down-titrated at any time during the study. Study medication was administered once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment.

Arm title	Placebo
------------------	---------

Arm description:

Subjects received matching placebo once daily in addition to standard of care therapy

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Matching placebo, oral tablet, once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment

Number of subjects in period 1	Finerenone	Placebo
Started	3686	3666
Treated	3683	3658
Completed	3681	3653
Not completed	5	13
Consent withdrawn by subject	1	7
Lost to follow-up	4	6

Baseline characteristics

Reporting groups

Reporting group title	Finerenone
Reporting group description:	
Subjects received finerenone 10 mg or 20 mg once daily in addition to standard of care therapy	
Reporting group title	Placebo
Reporting group description:	
Subjects received matching placebo once daily in addition to standard of care therapy	

Reporting group values	Finerenone	Placebo	Total
Number of subjects	3686	3666	7352
Age categorical			
Units: Subjects			

Age Continuous			
Units: years			
arithmetic mean	64.13	64.13	
standard deviation	± 9.67	± 10	-
Sex: Female, Male			
Units: Subjects			
Female	1158	1089	2247
Male	2528	2577	5105
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	73	70	143
Asian	715	739	1454
Native Hawaiian or Other Pacific Islander	17	14	31
Black or African American	113	145	258
White	2672	2605	5277
More than one race	87	86	173
Unknown or Not Reported	9	7	16
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	618	603	1221
Not Hispanic or Latino	3058	3057	6115
Unknown or Not Reported	10	6	16
Urinary albumin-to-creatinine ratio (UACR)			
Units: milligram/gram (mg/g)			
median	302.36	315.06	
inter-quartile range (Q1-Q3)	105.47 to 749.05	111.24 to 731.01	-
Estimated glomerular filtration rate (eGFR)			
Units: mL/min/1.73m ²			
arithmetic mean	67.62	67.99	
standard deviation	± 21.65	± 21.74	-

End points

End points reporting groups

Reporting group title	Finerenone
Reporting group description:	
Subjects received finerenone 10 mg or 20 mg once daily in addition to standard of care therapy	
Reporting group title	Placebo
Reporting group description:	
Subjects received matching placebo once daily in addition to standard of care therapy	
Subject analysis set title	Full analysis set (FAS)
Subject analysis set type	Full analysis
Subject analysis set description:	
The FAS comprised all randomized subjects (except those with critical GCP violations).	

Primary: The first occurrence of the composite endpoint of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure

End point title	The first occurrence of the composite endpoint of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure
End point description:	
Count of subjects and time from randomization to the first occurrence of the primary cardiovascular (CV) composite outcome, CV death, non-fatal myocardial infarction (MI), non-fatal stroke, or hospitalization for heart failure were evaluated. Number of subjects with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis.	
End point type	Primary
End point timeframe:	
From randomization up until the first occurrence of the CV composite endpoint, or censoring at the end of the study, with an average study duration of 41 months.	

End point values	Finerenone	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3686	3666		
Units: Subjects				
number (not applicable)	458	519		

Statistical analyses

Statistical analysis title	Primary CV composite endpoint
Statistical analysis description:	
A stratified Cox proportional hazards regression model was used to provide a point estimate of the hazard ratio and a corresponding two-sided 95% confidence interval and a stratified logrank test was conducted to produce a two-sided p-value.	
Comparison groups	Finerenone v Placebo

Number of subjects included in analysis	7352
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0264 ^[1]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.87
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.76
upper limit	0.98

Notes:

[1] - A hierarchical testing procedure was used for the primary and secondary efficacy endpoints with each variable being tested at the adjusted two-sided significance level of 0.04967388.

Secondary: The first occurrence of the composite endpoint of onset of kidney failure, a sustained decrease of eGFR \geq 40% from baseline over at least 4 weeks, or renal death

End point title	The first occurrence of the composite endpoint of onset of kidney failure, a sustained decrease of eGFR \geq 40% from baseline over at least 4 weeks, or renal death
-----------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Count of subjects and time from randomization to the first occurrence of the renal composite outcome, onset of kidney failure, a sustained decrease of eGFR \geq 40% from baseline over at least 4 weeks, or renal death were evaluated. Number of subjects with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization up until the first occurrence of the renal composite endpoint, or censoring at the end of the study, with an average study duration of 41 months

End point values	Finerenone	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3686	3666		
Units: Subjects				
number (not applicable)	350	395		

Statistical analyses

Statistical analysis title	Secondary 40% renal composite endpoint
-----------------------------------	----------------------------------------

Statistical analysis description:

A stratified Cox proportional hazards regression model was used to provide a point estimate of the hazard ratio and a corresponding two-sided 95% confidence interval and a stratified logrank test was conducted to produce a two-sided p-value.

Comparison groups	Finerenone v Placebo
-------------------	----------------------

Number of subjects included in analysis	7352
Analysis specification	Pre-specified
Analysis type	superiority ^[2]
P-value	= 0.0689 ^[3]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.87
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.76
upper limit	1.01

Notes:

[2] - As the treatment effect of the 40% renal composite endpoint was not significant, all other endpoints (i.e. all-cause hospitalization, all-cause mortality, change in UACR from baseline to Month 4, and 57% renal composite endpoint) were tested in an exploratory manner.

[3] - A hierarchical testing procedure was used for the primary and secondary efficacy endpoints with each variable being tested at the adjusted two-sided significance level of 0.04967388.

Secondary: All-cause hospitalization

End point title	All-cause hospitalization
End point description:	Count of subjects and time from randomization to the first occurrence of a hospitalization event were evaluated. Number of subjects with the event is reported as descriptive result and hazard ratio is reported as statistical analysis.
End point type	Secondary
End point timeframe:	From randomization up until the first occurrence of the hospitalization due to any cause, or censoring at the end of study, with an average study duration of 41 months

End point values	Finerenone	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3686	3666		
Units: Subjects				
number (not applicable)	1573	1605		

Statistical analyses

Statistical analysis title	All-cause hospitalization
Statistical analysis description:	A stratified Cox proportional hazards regression model was used to provide a point estimate of the hazard ratio and a corresponding two-sided 95% confidence interval and a stratified logrank test was conducted to produce a two-sided p-value.
Comparison groups	Finerenone v Placebo

Number of subjects included in analysis	7352
Analysis specification	Pre-specified
Analysis type	superiority ^[4]
P-value	= 0.3558 ^[5]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.97
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.9
upper limit	1.04

Notes:

[4] - As the treatment effect of the 40% renal composite endpoint was not significant, all other endpoints (i.e. all-cause hospitalization, all-cause mortality, change in UACR from baseline to Month 4, and 57% renal composite endpoint) were tested in an exploratory manner.

[5] - A hierarchical testing procedure was used for the primary and secondary efficacy endpoints with each variable being tested at the adjusted two-sided significance level of 0.04967388.

Secondary: All-cause mortality

End point title	All-cause mortality
End point description:	Count of subjects and time from randomization until death due to any cause were evaluated. Number of subjects with outcome death is reported as descriptive result and hazard ratio is reported as statistical analysis.
End point type	Secondary
End point timeframe:	From randomization up until death due to any cause, or censoring at the end of the study, with an average study duration of 41 months.

End point values	Finerenone	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3686	3666		
Units: Subjects				
number (not applicable)	333	370		

Statistical analyses

Statistical analysis title	All-cause mortality
Statistical analysis description:	A stratified Cox proportional hazards regression model was used to provide a point estimate of the hazard ratio and a corresponding two-sided 95% confidence interval and a stratified logrank test was conducted to produce a two-sided p-value.
Comparison groups	Finerenone v Placebo

Number of subjects included in analysis	7352
Analysis specification	Pre-specified
Analysis type	superiority ^[6]
P-value	= 0.1337 ^[7]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.89
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.77
upper limit	1.04

Notes:

[6] - As the treatment effect of the 40% renal composite endpoint was not significant, all other endpoints (i.e. all-cause hospitalization, all-cause mortality, change in UACR from baseline to Month 4, and 57% renal composite endpoint) were tested in an exploratory manner.

[7] - A hierarchical testing procedure was used for the primary and secondary efficacy endpoints with each variable being tested at the adjusted two-sided significance level of 0.04967388.

Secondary: Change in urinary albumin-to-creatinine ratio (UACR) from baseline to month 4

End point title	Change in urinary albumin-to-creatinine ratio (UACR) from baseline to month 4
-----------------	-------------------------------------------------------------------------------

End point description:

First morning void urine samples were collected to evaluate the urinary albumin-to-creatinine ratio (UACR). Month 4 was the visit closest to day 120 within a time window of 120 ± 30 days after randomization. If no measurements were available in this time window, the subject was excluded from this analysis. Ratio of UACR at Month 4 to UACR at baseline is reported as the change. The analysis was performed on the subjects in FAS with measurements available within the time window of Month 4.

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline up until Month 4

End point values	Finerenone	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3521	3476		
Units: Ratio				
least squares mean (confidence interval 95%)	0.624 (0.606 to 0.642)	0.922 (0.896 to 0.949)		

Statistical analyses

Statistical analysis title	Change in UACR from baseline to Month 4
Comparison groups	Finerenone v Placebo

Number of subjects included in analysis	6997
Analysis specification	Pre-specified
Analysis type	superiority ^[8]
P-value	< 0.0001 ^[9]
Method	ANCOVA
Parameter estimate	Ratio of least squares means
Point estimate	0.676
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.65
upper limit	0.704

Notes:

[8] - As the treatment effect of the 40% renal composite endpoint was not significant, all other endpoints (i.e. all-cause hospitalization, all-cause mortality, change in UACR from baseline to Month 4, and 57% renal composite endpoint) were tested in an exploratory manner.

[9] - P-value from F-test of equal means between the treatment groups. A hierarchical testing procedure was used for the primary and secondary efficacy endpoints with each variable being tested at the adjusted two-sided significance level of 0.04967388.

Secondary: The first occurrence of the composite endpoint of onset of kidney failure, a sustained decrease in eGFR of $\geq 57\%$ from baseline over at least 4 weeks, or renal death.

End point title	The first occurrence of the composite endpoint of onset of kidney failure, a sustained decrease in eGFR of $\geq 57\%$ from baseline over at least 4 weeks, or renal death.
-----------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Count of subjects and time from randomization to the first occurrence of the renal composite outcome, onset of kidney failure, a sustained decrease in eGFR of $\geq 57\%$ from baseline over at least 4 weeks, or renal death were evaluated. Number of subjects with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization up until the first occurrence of the renal composite endpoint, or censoring at the end of the study, with an average study duration of 41 months.

End point values	Finerenone	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3686	3666		
Units: Subjects				
number (not applicable)	108	139		

Statistical analyses

Statistical analysis title	Secondary 57% renal composite endpoint
-----------------------------------	----------------------------------------

Statistical analysis description:

A stratified Cox proportional hazards regression model was used to provide a point estimate of the hazard ratio and a corresponding two-sided 95% confidence interval and a stratified logrank test was conducted to produce a two-sided p-value.

Comparison groups	Finerenone v Placebo
-------------------	----------------------

Number of subjects included in analysis	7352
Analysis specification	Pre-specified
Analysis type	superiority ^[10]
P-value	= 0.0406 ^[11]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.77
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.6
upper limit	0.99

Notes:

[10] - As the treatment effect of the 40% renal composite endpoint was not significant, all other endpoints (i.e. all-cause hospitalization, all-cause mortality, change in UACR from baseline to Month 4, and 57% renal composite endpoint) were tested in an exploratory manner.

[11] - A hierarchical testing procedure was used for the primary and secondary efficacy endpoints with each variable being tested at the adjusted two-sided significance level of 0.04967388.

Adverse events

Adverse events information

Timeframe for reporting adverse events:

After the first dose of study drug up to 3 days after any temporary or permanent interruption of study drug, with an average treatment duration of 36 months

Adverse event reporting additional description:

Adverse event reporting for the numbers of deaths (all causes) considers all deaths in the safety analysis set (comprised all randomized subjects who took at least 1 dose of study drug [except those with critical GCP violations]) that occurred at any time during the study after the first dose of study drug (with an average duration of 41 months).

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.1
--------------------	------

Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Subjects received matching placebo once daily in addition to standard of care therapy

Reporting group title	Finerenone
-----------------------	------------

Reporting group description:

Subjects received finerenone 10 mg or 20 mg once daily in addition to standard of care therapy

Serious adverse events	Placebo	Finerenone	
Total subjects affected by serious adverse events			
subjects affected / exposed	1215 / 3658 (33.21%)	1158 / 3683 (31.44%)	
number of deaths (all causes)	382	338	
number of deaths resulting from adverse events	100	79	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute myeloid leukaemia			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Adenocarcinoma			
subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	2 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma gastric			

subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma of colon			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adrenal adenoma			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
B-cell lymphoma			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Basal cell carcinoma			
subjects affected / exposed	4 / 3658 (0.11%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign neoplasm of bladder			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign neoplasm of prostate			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer			
subjects affected / exposed	4 / 3658 (0.11%)	11 / 3683 (0.30%)	
occurrences causally related to treatment / all	0 / 4	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer recurrent			

subjects affected / exposed	0 / 3658 (0.00%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder neoplasm			
subjects affected / exposed	3 / 3658 (0.08%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder transitional cell carcinoma			
subjects affected / exposed	3 / 3658 (0.08%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone cancer			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer			
subjects affected / exposed	4 / 3658 (0.11%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchial carcinoma			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Cervix carcinoma			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangiocarcinoma			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 2	0 / 1	
Chronic lymphocytic leukaemia			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diffuse large B-cell lymphoma			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Colon cancer			
subjects affected / exposed	9 / 3658 (0.25%)	14 / 3683 (0.38%)	
occurrences causally related to treatment / all	0 / 10	1 / 15	
deaths causally related to treatment / all	0 / 1	0 / 2	
Enchondromatosis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial cancer			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial adenocarcinoma			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal carcinoma			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Gastric cancer			
subjects affected / exposed	2 / 3658 (0.05%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glioblastoma			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Haemangioblastoma			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypergammaglobulinaemia benign monoclonal			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypopharyngeal cancer			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung adenocarcinoma			
subjects affected / exposed	4 / 3658 (0.11%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 2	
Laryngeal squamous cell carcinoma			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphoma			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant melanoma			
subjects affected / exposed	3 / 3658 (0.08%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant pleural effusion			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningioma			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningioma benign			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to bone			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to lung			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Metastases to liver			
subjects affected / exposed	1 / 3658 (0.03%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to lymph nodes			
subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastatic malignant melanoma			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Myelodysplastic syndrome			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasm			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasm malignant			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasm prostate			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasm skin			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal adenocarcinoma			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal carcinoma			
subjects affected / exposed	5 / 3658 (0.14%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Oropharyngeal squamous cell carcinoma			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian cancer			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic carcinoma			
subjects affected / exposed	5 / 3658 (0.14%)	5 / 3683 (0.14%)	
occurrences causally related to treatment / all	1 / 5	0 / 5	
deaths causally related to treatment / all	0 / 3	0 / 1	
Pancreatic carcinoma metastatic			
subjects affected / exposed	2 / 3658 (0.05%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 2	0 / 0	
Papillary thyroid cancer			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Papilloma			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pituitary tumour			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Plasma cell myeloma			
subjects affected / exposed	1 / 3658 (0.03%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 2	
Prostate cancer metastatic			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Prostate cancer recurrent			

subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatic adenoma			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal adenocarcinoma			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cancer			
subjects affected / exposed	3 / 3658 (0.08%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Respiratory papilloma			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sarcoma			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Seminoma			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin cancer			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin papilloma			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small cell lung cancer			
subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
Squamous cell carcinoma			
subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of lung			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of skin			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of the oral cavity			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of the tongue			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thymoma			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid adenoma			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsil cancer			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transitional cell carcinoma			
subjects affected / exposed	1 / 3658 (0.03%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine cancer			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine leiomyoma			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon adenoma			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung cancer metastatic			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tumour ulceration			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colorectal adenocarcinoma			

subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Salivary gland adenoma			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma pancreas			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Gastrointestinal cancer metastatic			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Ear neoplasm malignant			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic cancer metastatic			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer metastatic			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retroperitoneal neoplasm			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuroendocrine carcinoma			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Choroid neoplasm			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Testis cancer			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung neoplasm malignant			
subjects affected / exposed	8 / 3658 (0.22%)	7 / 3683 (0.19%)	
occurrences causally related to treatment / all	0 / 8	0 / 7	
deaths causally related to treatment / all	0 / 4	0 / 2	
Metastases to central nervous system			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pancreatic carcinoma stage IV			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Prostate cancer			
subjects affected / exposed	24 / 3658 (0.66%)	10 / 3683 (0.27%)	
occurrences causally related to treatment / all	0 / 24	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign anorectal neoplasm			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign pancreatic neoplasm			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign gastrointestinal neoplasm			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain neoplasm			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon neoplasm			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Female reproductive neoplasm			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal cancer			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colorectal cancer			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal neoplasm			
subjects affected / exposed	2 / 3658 (0.05%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 0	
Ovarian neoplasm			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adrenal neoplasm			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal neoplasm			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic neoplasm			
subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
Lung neoplasm			
subjects affected / exposed	5 / 3658 (0.14%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 6	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Rectal neoplasm			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastasis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tumour invasion			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid cancer			

subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder transitional cell carcinoma recurrent			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cell carcinoma			
subjects affected / exposed	0 / 3658 (0.00%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemangioma of spleen			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epithelioid mesothelioma			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hepatic cancer			
subjects affected / exposed	4 / 3658 (0.11%)	5 / 3683 (0.14%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 3	0 / 3	
Hepatocellular carcinoma			
subjects affected / exposed	2 / 3658 (0.05%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	1 / 2	0 / 4	
deaths causally related to treatment / all	1 / 2	0 / 0	
Invasive lobular breast carcinoma			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Invasive papillary breast carcinoma			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clear cell renal cell carcinoma			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Papillary cystadenoma lymphomatosum			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Triple negative breast cancer			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Invasive breast carcinoma			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transitional cell carcinoma recurrent			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Papillary renal cell carcinoma			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of the parotid gland			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			

Aortic aneurysm			
subjects affected / exposed	1 / 3658 (0.03%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic dissection			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic stenosis			
subjects affected / exposed	2 / 3658 (0.05%)	5 / 3683 (0.14%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortitis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial thrombosis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Circulatory collapse			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Essential hypertension			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Giant cell arteritis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			
subjects affected / exposed	22 / 3658 (0.60%)	12 / 3683 (0.33%)	
occurrences causally related to treatment / all	0 / 28	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive crisis			
subjects affected / exposed	6 / 3658 (0.16%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 6	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orthostatic hypotension			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			
subjects affected / exposed	3 / 3658 (0.08%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral ischaemia			
subjects affected / exposed	5 / 3658 (0.14%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral vascular disorder			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Phlebitis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Shock			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Subclavian steal syndrome			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Systolic hypertension			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombophlebitis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombosis			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varicose ulceration			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varicose vein			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vasculitis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post thrombotic syndrome			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Labile hypertension			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dry gangrene			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deep vein thrombosis			
subjects affected / exposed	5 / 3658 (0.14%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery aneurysm			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery occlusion			
subjects affected / exposed	2 / 3658 (0.05%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive emergency			
subjects affected / exposed	3 / 3658 (0.08%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive urgency			
subjects affected / exposed	4 / 3658 (0.11%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extremity necrosis			

subjects affected / exposed	1 / 3658 (0.03%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral embolism			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic vascular disorder			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral arterial occlusive disease			
subjects affected / exposed	6 / 3658 (0.16%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 7	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subclavian artery occlusion			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery stenosis			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery thrombosis			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery aneurysm rupture			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
Abscess drainage			

subjects affected / exposed	3 / 3658 (0.08%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic aneurysm repair			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve replacement			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicectomy			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriovenous fistula operation			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder calculus removal			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder neck resection			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac pacemaker insertion			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid endarterectomy			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystectomy			
subjects affected / exposed	7 / 3658 (0.19%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 7	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Circumcision			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery bypass			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Finger amputation			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot amputation			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip arthroplasty			
subjects affected / exposed	2 / 3658 (0.05%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hysterectomy			
subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incisional hernia repair			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia repair			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intensive care			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Insertion of ambulatory peritoneal catheter			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Internal fixation of fracture			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Knee arthroplasty			
subjects affected / exposed	9 / 3658 (0.25%)	8 / 3683 (0.22%)	
occurrences causally related to treatment / all	0 / 9	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leg amputation			
subjects affected / exposed	5 / 3658 (0.14%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lipoma excision			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung lobectomy			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasal polypectomy			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parathyroidectomy			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parotidectomy			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radical hysterectomy			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radioactive iodine therapy			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Removal of foreign body from larynx			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Removal of internal fixation			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cyst excision			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal stone removal			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scar excision			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Roux loop conversion			
subjects affected / exposed	0 / 3658 (0.00%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin ulcer excision			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal laminectomy			
subjects affected / exposed	1 / 3658 (0.03%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal decompression			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toe amputation			
subjects affected / exposed	3 / 3658 (0.08%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Umbilical hernia repair			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transurethral prostatectomy			
subjects affected / exposed	4 / 3658 (0.11%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine polypectomy			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitrectomy			
subjects affected / exposed	2 / 3658 (0.05%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Implantable defibrillator insertion			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Knee operation			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Shoulder arthroplasty			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary revascularisation			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureteral stent insertion			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radical prostatectomy			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus management			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Preoperative care			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transurethral bladder resection			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neurolysis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polypectomy			
subjects affected / exposed	3 / 3658 (0.08%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Caecum operation			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc operation			

subjects affected / exposed	4 / 3658 (0.11%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery angioplasty			
subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral nerve decompression			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin neoplasm excision			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Proctocolectomy			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac ablation			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brachytherapy			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb operation			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic surgery			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone operation			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chemotherapy			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colectomy			
subjects affected / exposed	0 / 3658 (0.00%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye operation			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eyelid operation			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatectomy			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrectomy			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric bypass			

subjects affected / exposed	2 / 3658 (0.05%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrocele operation			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lithotripsy			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal operation			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroidectomy			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tooth extraction			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varicose vein operation			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin graft			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal operation			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug therapy			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular stent insertion			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract operation			
subjects affected / exposed	3 / 3658 (0.08%)	7 / 3683 (0.19%)	
occurrences causally related to treatment / all	0 / 5	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectocele repair			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Percutaneous coronary intervention			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intraocular lens implant			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neurosurgery			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic stent placement			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery bypass			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestinal polypectomy			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast conserving surgery			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transcatheter aortic valve implantation			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial appendage closure			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic surgery			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cheilectomy			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary catheter removal			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal disorder prophylaxis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug delivery device placement			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ocular stem cell transplant			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	2 / 3658 (0.05%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest pain			
subjects affected / exposed	20 / 3658 (0.55%)	18 / 3683 (0.49%)	
occurrences causally related to treatment / all	0 / 22	0 / 18	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death			
subjects affected / exposed	6 / 3658 (0.16%)	8 / 3683 (0.22%)	
occurrences causally related to treatment / all	1 / 6	0 / 8	
deaths causally related to treatment / all	1 / 6	0 / 8	
Generalised oedema			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired healing			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malaise			
subjects affected / exposed	3 / 3658 (0.08%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	1 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema			
subjects affected / exposed	2 / 3658 (0.05%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema peripheral			
subjects affected / exposed	9 / 3658 (0.25%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	1 / 21	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	5 / 3658 (0.14%)	6 / 3683 (0.16%)	
occurrences causally related to treatment / all	0 / 6	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden death			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Peripheral swelling			
subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			

subjects affected / exposed	8 / 3658 (0.22%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 10	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 0	
Oedema due to cardiac disease			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Systemic inflammatory response syndrome			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Haemorrhagic cyst			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adhesion			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyp			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug intolerance			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-cardiac chest pain			
subjects affected / exposed	3 / 3658 (0.08%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Complication associated with device			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple organ dysfunction syndrome			
subjects affected / exposed	2 / 3658 (0.05%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 0	
Hanging			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaphylactic shock			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Reproductive system and breast disorders			
Benign prostatic hyperplasia			
subjects affected / exposed	10 / 3658 (0.27%)	12 / 3683 (0.33%)	
occurrences causally related to treatment / all	0 / 10	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast mass			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast necrosis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Endometrial hyperplasia			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian cyst			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Prostatic disorder			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatism			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatitis			
subjects affected / exposed	3 / 3658 (0.08%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine polyp			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatomegaly			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Female genital tract fistula			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erectile dysfunction			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scrotal dermatitis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Acute pulmonary oedema			
subjects affected / exposed	4 / 3658 (0.11%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute respiratory failure			
subjects affected / exposed	9 / 3658 (0.25%)	12 / 3683 (0.33%)	
occurrences causally related to treatment / all	0 / 10	0 / 12	
deaths causally related to treatment / all	0 / 4	0 / 2	
Asphyxia			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Aspiration			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Asthma			
subjects affected / exposed	5 / 3658 (0.14%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchiectasis			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Bronchitis chronic			

subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchospasm			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic obstructive pulmonary disease			
subjects affected / exposed	16 / 3658 (0.44%)	22 / 3683 (0.60%)	
occurrences causally related to treatment / all	0 / 26	0 / 24	
deaths causally related to treatment / all	0 / 1	0 / 0	
Chronic respiratory failure			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cough			
subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysphonia			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	9 / 3658 (0.25%)	9 / 3683 (0.24%)	
occurrences causally related to treatment / all	0 / 10	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea exertional			
subjects affected / exposed	2 / 3658 (0.05%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epistaxis			

subjects affected / exposed	2 / 3658 (0.05%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoptysis			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hiccups			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercapnia			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxia			
subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Idiopathic pulmonary fibrosis			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Interstitial lung disease			
subjects affected / exposed	4 / 3658 (0.11%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngeal oedema			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung disorder			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasal septum deviation			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			
subjects affected / exposed	7 / 3658 (0.19%)	5 / 3683 (0.14%)	
occurrences causally related to treatment / all	0 / 10	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pneumonia aspiration			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pulmonary congestion			
subjects affected / exposed	4 / 3658 (0.11%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 6	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pulmonary embolism			
subjects affected / exposed	11 / 3658 (0.30%)	6 / 3683 (0.16%)	
occurrences causally related to treatment / all	0 / 11	0 / 6	
deaths causally related to treatment / all	0 / 2	0 / 0	
Pulmonary hypertension			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary infarction			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary oedema			
subjects affected / exposed	5 / 3658 (0.14%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 6	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Respiratory acidosis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory arrest			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Respiratory disorder			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory distress			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	9 / 3658 (0.25%)	6 / 3683 (0.16%)	
occurrences causally related to treatment / all	0 / 12	0 / 6	
deaths causally related to treatment / all	0 / 2	0 / 1	
Sleep apnoea syndrome			
subjects affected / exposed	4 / 3658 (0.11%)	5 / 3683 (0.14%)	
occurrences causally related to treatment / all	0 / 5	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngeal mass			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary mass			
subjects affected / exposed	0 / 3658 (0.00%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Laryngeal disorder			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obstructive airways disorder			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthmatic crisis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchial hyperreactivity			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic hydrothorax			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alveolar lung disease			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung perforation			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small airways disease			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Completed suicide			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Confusional state			
subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Delusional disorder, unspecified type			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression			
subjects affected / exposed	2 / 3658 (0.05%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug abuse			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental status changes			

subjects affected / exposed	2 / 3658 (0.05%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bipolar disorder			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Major depression			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental disorder due to a general medical condition			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicide threat			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Product issues			
Device malfunction			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device loosening			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Bile duct stone			
subjects affected / exposed	3 / 3658 (0.08%)	5 / 3683 (0.14%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	

Biliary colic			
subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary fistula			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis			
subjects affected / exposed	3 / 3658 (0.08%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis acute			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis			
subjects affected / exposed	5 / 3658 (0.14%)	7 / 3683 (0.19%)	
occurrences causally related to treatment / all	0 / 5	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis acute			
subjects affected / exposed	7 / 3658 (0.19%)	9 / 3683 (0.24%)	
occurrences causally related to treatment / all	0 / 7	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis chronic			
subjects affected / exposed	0 / 3658 (0.00%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholelithiasis			
subjects affected / exposed	7 / 3658 (0.19%)	5 / 3683 (0.14%)	
occurrences causally related to treatment / all	0 / 9	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic hepatitis			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cirrhosis alcoholic			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fatty liver alcoholic			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hepatic cirrhosis			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hepatic failure			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hepatic function abnormal			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis acute			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatorenal syndrome			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Jaundice			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jaundice cholestatic			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Liver disorder			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Portal hypertension			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Portal vein thrombosis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystocholangitis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder polyp			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-alcoholic steatohepatitis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary dyskinesia			

subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Primary biliary cholangitis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Arthroscopy			
subjects affected / exposed	3 / 3658 (0.08%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biopsy bladder			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biopsy kidney			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biopsy liver			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biopsy prostate			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatine phosphokinase increased			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatinine increased			

subjects affected / exposed	3 / 3658 (0.08%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 3	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood glucose increased			
subjects affected / exposed	4 / 3658 (0.11%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood magnesium decreased			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood potassium decreased			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood potassium increased			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood pressure increased			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
C-reactive protein increased			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colonoscopy			
subjects affected / exposed	2 / 3658 (0.05%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colonoscopy normal			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Computerised tomogram			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrocardiogram abnormal			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endoscopy			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glomerular filtration rate decreased			
subjects affected / exposed	1 / 3658 (0.03%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glycosylated haemoglobin increased			
subjects affected / exposed	3 / 3658 (0.08%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematocrit decreased			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood urine present			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
International normalised ratio increased			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Weight decreased			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angiogram cerebral			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sleep study			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood pressure orthostatic decreased			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Troponin increased			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac function test abnormal			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anticoagulation drug level below therapeutic			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic enzyme increased			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angiogram			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigation			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory syncytial virus test positive			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza A virus test positive			
subjects affected / exposed	4 / 3658 (0.11%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endobronchial ultrasound			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver function test increased			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal stoma output increased			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cancer staging			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angiocardiogram			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SARS-CoV-2 test positive			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SARS-CoV-2 test negative			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Accident			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Accidental overdose			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acetabulum fracture			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Animal bite			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ankle fracture			

subjects affected / exposed	6 / 3658 (0.16%)	6 / 3683 (0.16%)	
occurrences causally related to treatment / all	0 / 6	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cartilage injury			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clavicle fracture			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Concussion			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis radiation			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial bones fracture			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fall			
subjects affected / exposed	5 / 3658 (0.14%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Femoral neck fracture			
subjects affected / exposed	0 / 3658 (0.00%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femur fracture			

subjects affected / exposed	8 / 3658 (0.22%)	8 / 3683 (0.22%)	
occurrences causally related to treatment / all	0 / 8	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibula fracture			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot fracture			
subjects affected / exposed	3 / 3658 (0.08%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foreign body aspiration			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gun shot wound			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hand fracture			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Head injury			
subjects affected / exposed	2 / 3658 (0.05%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip fracture			
subjects affected / exposed	2 / 3658 (0.05%)	5 / 3683 (0.14%)	
occurrences causally related to treatment / all	0 / 2	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Humerus fracture			

subjects affected / exposed	4 / 3658 (0.11%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury corneal			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint dislocation			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple fractures			
subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Multiple injuries			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Overdose			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Patella fracture			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radiation proctitis			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radius fracture			
subjects affected / exposed	5 / 3658 (0.14%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rib fracture			
subjects affected / exposed	4 / 3658 (0.11%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Road traffic accident			
subjects affected / exposed	2 / 3658 (0.05%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 2	
Scapula fracture			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skull fractured base			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal compression fracture			
subjects affected / exposed	2 / 3658 (0.05%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal fracture			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenic injury			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haematoma			
subjects affected / exposed	6 / 3658 (0.16%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haemorrhage			
subjects affected / exposed	3 / 3658 (0.08%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendon rupture			
subjects affected / exposed	2 / 3658 (0.05%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tibia fracture			
subjects affected / exposed	1 / 3658 (0.03%)	5 / 3683 (0.14%)	
occurrences causally related to treatment / all	0 / 1	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic ulcer			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ulna fracture			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular injury			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia postoperative			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular pseudoaneurysm			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic fracture			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar vertebral fracture			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Contusion			
subjects affected / exposed	2 / 3658 (0.05%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haemorrhage			
subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain contusion			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thermal burn			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Intervertebral disc injury			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac procedure complication			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Procedural complication			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin laceration			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint injury			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal injury			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pelvic fracture			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb injury			
subjects affected / exposed	3 / 3658 (0.08%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Poisoning			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Skin injury			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skull fracture			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest injury			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic intracranial haemorrhage			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper limb fracture			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative wound complication			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower limb fracture			
subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stomal hernia			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular anastomosis aneurysm			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haematoma			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral hyperperfusion syndrome			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin abrasion			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ligament rupture			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone contusion			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Heat illness			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound contamination			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periprosthetic fracture			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxicity to various agents			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Craniocerebral injury			
subjects affected / exposed	2 / 3658 (0.05%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Procedural haemorrhage			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin wound			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meniscus injury			
subjects affected / exposed	2 / 3658 (0.05%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye contusion			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural intestinal perforation			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative delirium			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dental restoration failure			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ocular procedural complication			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive tract procedural complication			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital, familial and genetic disorders			
Arnold-Chiari malformation			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypospadias			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Phimosis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenomatous polyposis coli			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anomaly of middle ear congenital			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina pectoris			
subjects affected / exposed	2 / 3658 (0.05%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina unstable			
subjects affected / exposed	1 / 3658 (0.03%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve disease mixed			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve incompetence			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve stenosis			
subjects affected / exposed	3 / 3658 (0.08%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arrhythmia			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriosclerosis coronary artery			
subjects affected / exposed	1 / 3658 (0.03%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 0	
Atrial fibrillation			
subjects affected / exposed	2 / 3658 (0.05%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial flutter			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block complete			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block second degree			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bradycardia			
subjects affected / exposed	2 / 3658 (0.05%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bundle branch block left			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac arrest			

subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cardiac failure			
subjects affected / exposed	10 / 3658 (0.27%)	5 / 3683 (0.14%)	
occurrences causally related to treatment / all	0 / 10	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure acute			
subjects affected / exposed	0 / 3658 (0.00%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cardiac failure chronic			
subjects affected / exposed	3 / 3658 (0.08%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure congestive			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardio-respiratory arrest			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiogenic shock			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiomyopathy			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cor pulmonale chronic			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery disease			
subjects affected / exposed	6 / 3658 (0.16%)	5 / 3683 (0.14%)	
occurrences causally related to treatment / all	0 / 6	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery occlusion			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery stenosis			
subjects affected / exposed	2 / 3658 (0.05%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	1 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extrasystoles			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial ischaemia			
subjects affected / exposed	3 / 3658 (0.08%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Palpitations			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial haemorrhage			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericarditis			

subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinoatrial block			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Supraventricular tachycardia			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachycardia			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular fibrillation			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular tachycardia			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Left ventricular hypertrophy			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Ventricular hypokinesia			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiopulmonary failure			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Acute coronary syndrome			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulseless electrical activity			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac valve disease			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute left ventricular failure			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Supraventricular tachyarrhythmia			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus node dysfunction			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paroxysmal atrioventricular block			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac dysfunction			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Altered state of consciousness			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Amnesia			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aphasia			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ataxia			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain stem haemorrhage			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Carotid artery stenosis			
subjects affected / exposed	4 / 3658 (0.11%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carpal tunnel syndrome			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cauda equina syndrome			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral haemorrhage			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral infarction			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral ischaemia			
subjects affected / exposed	0 / 3658 (0.00%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrospinal fluid leakage			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular accident			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular disorder			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervicobrachial syndrome			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coma			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dementia			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dementia Alzheimer's type			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic hyperosmolar coma			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic ketoacidotic hyperglycaemic coma			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Diabetic neuropathy			
subjects affected / exposed	7 / 3658 (0.19%)	11 / 3683 (0.30%)	
occurrences causally related to treatment / all	0 / 9	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness			
subjects affected / exposed	8 / 3658 (0.22%)	7 / 3683 (0.19%)	
occurrences causally related to treatment / all	1 / 8	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness postural			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysarthria			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyskinesia			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Encephalopathy			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial paralysis			
subjects affected / exposed	2 / 3658 (0.05%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epilepsy			
subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Generalised tonic-clonic seizure			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Guillain-Barre syndrome			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Headache			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hemiparesis			

subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic encephalopathy			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrocephalus			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoaesthesia			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive encephalopathy			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemic coma			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intracranial aneurysm			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
IIIrd nerve paralysis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intraventricular haemorrhage			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lethargy			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Loss of consciousness			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Memory impairment			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meralgia paraesthetica			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Migraine			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Moyamoya disease			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myelopathy			
subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuralgia			

subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuropathy peripheral			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Normal pressure hydrocephalus			
subjects affected / exposed	0 / 3658 (0.00%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paraesthesia			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyneuropathy			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Presyncope			
subjects affected / exposed	2 / 3658 (0.05%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radiculopathy			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sciatica			
subjects affected / exposed	1 / 3658 (0.03%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure			

subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sensory disturbance			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Somnolence			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal cord compression			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spondylitic myelopathy			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subarachnoid haemorrhage			
subjects affected / exposed	4 / 3658 (0.11%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 0	
Syncope			
subjects affected / exposed	16 / 3658 (0.44%)	14 / 3683 (0.38%)	
occurrences causally related to treatment / all	1 / 16	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tension headache			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxic encephalopathy			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient ischaemic attack			
subjects affected / exposed	2 / 3658 (0.05%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ulnar neuritis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular headache			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo CNS origin			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Balance disorder			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical radiculopathy			
subjects affected / exposed	3 / 3658 (0.08%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar radiculopathy			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysstasia			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lacunar infarction			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial paresis			
subjects affected / exposed	3 / 3658 (0.08%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic inflammatory demyelinating polyradiculoneuropathy			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cognitive disorder			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic stroke			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Partial seizures			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial nerve disorder			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parkinson's disease			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic encephalopathy			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mononeuropathy			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular encephalopathy			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemic unconsciousness			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Amputation stump pain			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxic-ischaemic encephalopathy			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemic unconsciousness			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral nerve paresis			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intensive care unit acquired weakness			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Posthaemorrhagic hydrocephalus			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Central nervous system vasculitis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	15 / 3658 (0.41%)	18 / 3683 (0.49%)	
occurrences causally related to treatment / all	0 / 15	0 / 21	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coagulopathy			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Febrile neutropenia			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hilar lymphadenopathy			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypocoagulable state			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iron deficiency anaemia			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukocytosis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenopathy mediastinal			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Microcytic anaemia			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenia			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Normochromic normocytic anaemia			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypereosinophilic syndrome			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acquired haemophilia			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bicytopenia			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood loss anaemia			
subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Deafness			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tympanic membrane perforation			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo			
subjects affected / exposed	6 / 3658 (0.16%)	7 / 3683 (0.19%)	
occurrences causally related to treatment / all	0 / 6	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo positional			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vestibular ataxia			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vestibular disorder			

subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden hearing loss			
subjects affected / exposed	3 / 3658 (0.08%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute vestibular syndrome			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Cataract			
subjects affected / exposed	11 / 3658 (0.30%)	15 / 3683 (0.41%)	
occurrences causally related to treatment / all	0 / 16	0 / 18	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract diabetic			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract nuclear			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatochalasis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic eye disease			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic retinopathy			

subjects affected / exposed	7 / 3658 (0.19%)	11 / 3683 (0.30%)	
occurrences causally related to treatment / all	0 / 8	0 / 21	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diplopia			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extraocular muscle paresis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye haemorrhage			
subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glaucoma			
subjects affected / exposed	3 / 3658 (0.08%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 3	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Macular oedema			
subjects affected / exposed	3 / 3658 (0.08%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ophthalmoplegia			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Optic ischaemic neuropathy			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal detachment			

subjects affected / exposed	3 / 3658 (0.08%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal haemorrhage			
subjects affected / exposed	3 / 3658 (0.08%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinopathy			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinopathy proliferative			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vision blurred			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitreous haemorrhage			
subjects affected / exposed	7 / 3658 (0.19%)	16 / 3683 (0.43%)	
occurrences causally related to treatment / all	0 / 8	1 / 23	
deaths causally related to treatment / all	0 / 0	0 / 0	
Macular hole			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eyelid cyst			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Age-related macular degeneration			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ulcerative keratitis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhegmatogenous retinal detachment			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ocular ischaemic syndrome			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Macular fibrosis			
subjects affected / exposed	2 / 3658 (0.05%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal adhesions			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal mass			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain			
subjects affected / exposed	6 / 3658 (0.16%)	5 / 3683 (0.14%)	
occurrences causally related to treatment / all	0 / 6	1 / 5	
deaths causally related to treatment / all	0 / 0	0 / 1	
Abdominal pain lower			

subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain upper			
subjects affected / exposed	4 / 3658 (0.11%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal fistula			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ascites			
subjects affected / exposed	3 / 3658 (0.08%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Barrett's oesophagus			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic gastritis			
subjects affected / exposed	2 / 3658 (0.05%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	1 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis ischaemic			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis ulcerative			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	4 / 3658 (0.11%)	7 / 3683 (0.19%)	
occurrences causally related to treatment / all	1 / 4	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal perforation			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer			
subjects affected / exposed	2 / 3658 (0.05%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer haemorrhage			
subjects affected / exposed	3 / 3658 (0.08%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Dyspepsia			
subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enteritis			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Food poisoning			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric haemorrhage			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric polyps			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer			
subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer haemorrhage			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis			
subjects affected / exposed	2 / 3658 (0.05%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis erosive			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis haemorrhagic			

subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrooesophageal reflux disease			
subjects affected / exposed	4 / 3658 (0.11%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroduodenal ulcer			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			
subjects affected / exposed	9 / 3658 (0.25%)	7 / 3683 (0.19%)	
occurrences causally related to treatment / all	0 / 12	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal pain			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematemesis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematochezia			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoids			
subjects affected / exposed	1 / 3658 (0.03%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus paralytic			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired gastric emptying			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia			
subjects affected / exposed	9 / 3658 (0.25%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 10	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal ischaemia			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Intestinal obstruction			
subjects affected / exposed	7 / 3658 (0.19%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 11	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Melaena			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mesenteric vein thrombosis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mouth haemorrhage			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal haemorrhage			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal obstruction			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal varices haemorrhage			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophagitis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic cyst			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis			
subjects affected / exposed	1 / 3658 (0.03%)	5 / 3683 (0.14%)	
occurrences causally related to treatment / all	0 / 1	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis acute			

subjects affected / exposed	4 / 3658 (0.11%)	12 / 3683 (0.33%)	
occurrences causally related to treatment / all	0 / 4	0 / 16	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis chronic			
subjects affected / exposed	3 / 3658 (0.08%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis necrotising			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis relapsing			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parotid gland enlargement			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peptic ulcer			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Peptic ulcer haemorrhage			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal haemorrhage			
subjects affected / exposed	3 / 3658 (0.08%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal polyp			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			
subjects affected / exposed	4 / 3658 (0.11%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal perforation			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Swollen tongue			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Umbilical hernia			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper gastrointestinal haemorrhage			
subjects affected / exposed	6 / 3658 (0.16%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 6	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 0	
Volvulus			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	3 / 3658 (0.08%)	5 / 3683 (0.14%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic mass			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal discharge			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal haemorrhage			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric dysplasia			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal dysplasia			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subileus			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mechanical ileus			
subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine polyp			

subjects affected / exposed	11 / 3658 (0.30%)	14 / 3683 (0.38%)	
occurrences causally related to treatment / all	0 / 13	0 / 16	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal polyp			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Internal hernia			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedematous pancreatitis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal haemorrhage			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varices oesophageal			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric varices haemorrhage			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reflux gastritis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal oedema			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal mass			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal symptom			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal hernia			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric mucosal lesion			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticular perforation			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salivary gland disorder			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal inflammation			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incarcerated umbilical hernia			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic duct stenosis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal wall haematoma			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic erosive gastritis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Abdominal wall haemorrhage			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Omental infarction			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Functional gastrointestinal disorder			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal hernia perforation			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Dental cyst			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Angioedema			
subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blister			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Decubitus ulcer			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatitis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatitis allergic			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hidradenitis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ingrowing nail			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Palmoplantar keratoderma			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pemphigoid			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	1 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin necrosis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin ulcer			
subjects affected / exposed	15 / 3658 (0.41%)	12 / 3683 (0.33%)	
occurrences causally related to treatment / all	0 / 20	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 1	
Neuropathic ulcer			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic ulcer			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Necrobiosis lipoidica diabetorum			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxic skin eruption			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic foot			
subjects affected / exposed	18 / 3658 (0.49%)	23 / 3683 (0.62%)	
occurrences causally related to treatment / all	0 / 22	0 / 24	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angiokeratoma			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reactive perforating collagenosis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic cheiroarthropathy			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Albuminuria			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Azotaemia			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus bladder			
subjects affected / exposed	1 / 3658 (0.03%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus urinary			

subjects affected / exposed	3 / 3658 (0.08%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glomerulonephritis chronic			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glomerulonephritis membranous			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematuria			
subjects affected / exposed	6 / 3658 (0.16%)	5 / 3683 (0.14%)	
occurrences causally related to treatment / all	0 / 6	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydronephrosis			
subjects affected / exposed	4 / 3658 (0.11%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrolithiasis			
subjects affected / exposed	8 / 3658 (0.22%)	12 / 3683 (0.33%)	
occurrences causally related to treatment / all	0 / 11	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephropathy			
subjects affected / exposed	2 / 3658 (0.05%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrotic syndrome			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Proteinuria			

subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal artery stenosis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal colic			
subjects affected / exposed	2 / 3658 (0.05%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cyst			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			
subjects affected / exposed	2 / 3658 (0.05%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 2	2 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary hesitation			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureteric obstruction			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary incontinence			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary retention			

subjects affected / exposed	5 / 3658 (0.14%)	5 / 3683 (0.14%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vesicoureteric reflux			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract disorder			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tubulointerstitial nephritis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder neck sclerosis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract obstruction			
subjects affected / exposed	2 / 3658 (0.05%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic nephropathy			
subjects affected / exposed	26 / 3658 (0.71%)	10 / 3683 (0.27%)	
occurrences causally related to treatment / all	0 / 38	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal impairment			
subjects affected / exposed	4 / 3658 (0.11%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic kidney disease			

subjects affected / exposed	6 / 3658 (0.16%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	1 / 6	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral stenosis			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stress urinary incontinence			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute kidney injury			
subjects affected / exposed	46 / 3658 (1.26%)	38 / 3683 (1.03%)	
occurrences causally related to treatment / all	3 / 48	9 / 39	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower urinary tract symptoms			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
End stage renal disease			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureterolithiasis			
subjects affected / exposed	5 / 3658 (0.14%)	6 / 3683 (0.16%)	
occurrences causally related to treatment / all	0 / 6	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subacute kidney injury			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Goitre			

subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperparathyroidism			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypothyroidism			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Primary hyperaldosteronism			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxic nodular goitre			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Ankylosing spondylitis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthralgia			
subjects affected / exposed	6 / 3658 (0.16%)	6 / 3683 (0.16%)	
occurrences causally related to treatment / all	0 / 7	1 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis			
subjects affected / exposed	3 / 3658 (0.08%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis reactive			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthropathy			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back pain			
subjects affected / exposed	3 / 3658 (0.08%)	8 / 3683 (0.22%)	
occurrences causally related to treatment / all	0 / 3	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bursitis			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical spinal stenosis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chondromalacia			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Costochondritis			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dupuytren's contracture			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Exostosis			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fasciitis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gouty arthritis			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Groin pain			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemarthrosis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar spinal stenosis			
subjects affected / exposed	1 / 3658 (0.03%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle haemorrhage			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle spasms			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscular weakness			

subjects affected / exposed	2 / 3658 (0.05%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myalgia			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myositis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neck pain			
subjects affected / exposed	5 / 3658 (0.14%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuropathic arthropathy			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteitis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis			
subjects affected / exposed	9 / 3658 (0.25%)	22 / 3683 (0.60%)	
occurrences causally related to treatment / all	0 / 11	0 / 23	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteolysis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteonecrosis			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain in extremity			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoporosis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periarthritis			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pathological fracture			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Plantar fascial fibromatosis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psoriatic arthropathy			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 13	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Resorption bone increased			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhabdomyolysis			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rotator cuff syndrome			
subjects affected / exposed	4 / 3658 (0.11%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal osteoarthritis			
subjects affected / exposed	4 / 3658 (0.11%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Synovial cyst			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal chest pain			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc protrusion			
subjects affected / exposed	9 / 3658 (0.25%)	8 / 3683 (0.22%)	
occurrences causally related to treatment / all	0 / 9	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spondyloarthropathy			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Soft tissue haemorrhage			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal discomfort			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc compression			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facet joint syndrome			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tenosynovitis stenosaurs			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot deformity			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal ligament ossification			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc degeneration			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc disorder			
subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spondylolisthesis			

subjects affected / exposed	0 / 3658 (0.00%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inclusion body myositis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebral foraminal stenosis			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal pain			
subjects affected / exposed	3 / 3658 (0.08%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diastasis recti abdominis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendon discomfort			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebral lateral recess stenosis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal stenosis			
subjects affected / exposed	3 / 3658 (0.08%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immobilisation syndrome			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Abdominal wall abscess			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute sinusitis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anorectal cellulitis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis			
subjects affected / exposed	5 / 3658 (0.14%)	5 / 3683 (0.14%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriosclerotic gangrene			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aspergilloma			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atypical pneumonia			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteraemia			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			
subjects affected / exposed	9 / 3658 (0.25%)	7 / 3683 (0.19%)	
occurrences causally related to treatment / all	0 / 9	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Campylobacter gastroenteritis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	28 / 3658 (0.77%)	40 / 3683 (1.09%)	
occurrences causally related to treatment / all	0 / 29	0 / 46	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cellulitis gangrenous			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis staphylococcal			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic hepatitis C			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic sinusitis			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Corneal abscess			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis			
subjects affected / exposed	4 / 3658 (0.11%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dengue fever			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic gangrene			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			
subjects affected / exposed	4 / 3658 (0.11%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis intestinal haemorrhagic			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocarditis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterococcal bacteraemia			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epididymitis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erysipelas			
subjects affected / exposed	15 / 3658 (0.41%)	10 / 3683 (0.27%)	
occurrences causally related to treatment / all	0 / 21	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia sepsis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye infection			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fournier's gangrene			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Furuncle			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gangrene			
subjects affected / exposed	6 / 3658 (0.16%)	5 / 3683 (0.14%)	
occurrences causally related to treatment / all	0 / 7	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			

subjects affected / exposed	15 / 3658 (0.41%)	11 / 3683 (0.30%)	
occurrences causally related to treatment / all	0 / 15	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis rotavirus			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis salmonella			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis viral			
subjects affected / exposed	0 / 3658 (0.00%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster			
subjects affected / exposed	1 / 3658 (0.03%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
HIV infection			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected skin ulcer			
subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection			
subjects affected / exposed	5 / 3658 (0.14%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infectious mononucleosis			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infective myositis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza			
subjects affected / exposed	6 / 3658 (0.16%)	5 / 3683 (0.14%)	
occurrences causally related to treatment / all	0 / 6	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Labyrinthitis			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Localised infection			
subjects affected / exposed	6 / 3658 (0.16%)	9 / 3683 (0.24%)	
occurrences causally related to treatment / all	0 / 6	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection			
subjects affected / exposed	5 / 3658 (0.14%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mastoiditis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Necrotising fasciitis			

subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orchitis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis			
subjects affected / exposed	13 / 3658 (0.36%)	12 / 3683 (0.33%)	
occurrences causally related to treatment / all	0 / 13	0 / 16	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis acute			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis chronic			
subjects affected / exposed	2 / 3658 (0.05%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis externa			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis media			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paronychia			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic inflammatory disease			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonitis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonsillar abscess			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngitis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pilonidal cyst			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	113 / 3658 (3.09%)	73 / 3683 (1.98%)	
occurrences causally related to treatment / all	1 / 121	0 / 77	
deaths causally related to treatment / all	0 / 7	0 / 4	
Pneumonia haemophilus			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia influenzal			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia klebsiella			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia legionella			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia pneumococcal			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia streptococcal			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia viral			
subjects affected / exposed	1 / 3658 (0.03%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative wound infection			
subjects affected / exposed	2 / 3658 (0.05%)	7 / 3683 (0.19%)	
occurrences causally related to treatment / all	0 / 2	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatic abscess			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary mycosis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary tuberculosis			

subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pyelitis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis			
subjects affected / exposed	4 / 3658 (0.11%)	9 / 3683 (0.24%)	
occurrences causally related to treatment / all	0 / 4	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis acute			
subjects affected / exposed	2 / 3658 (0.05%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis chronic			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salpingitis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	20 / 3658 (0.55%)	16 / 3683 (0.43%)	
occurrences causally related to treatment / all	0 / 21	1 / 16	
deaths causally related to treatment / all	0 / 4	0 / 1	
Septic shock			
subjects affected / exposed	5 / 3658 (0.14%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 1	
Sialoadenitis			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin infection			
subjects affected / exposed	4 / 3658 (0.11%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Subacute endocarditis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subcutaneous abscess			
subjects affected / exposed	0 / 3658 (0.00%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tooth abscess			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheobronchitis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tuberculosis			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract infection			
subjects affected / exposed	5 / 3658 (0.14%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			

subjects affected / exposed	39 / 3658 (1.07%)	28 / 3683 (0.76%)	
occurrences causally related to treatment / all	0 / 40	0 / 33	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vestibular neuronitis			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral infection			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection			
subjects affected / exposed	4 / 3658 (0.11%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urosepsis			
subjects affected / exposed	13 / 3658 (0.36%)	12 / 3683 (0.33%)	
occurrences causally related to treatment / all	0 / 13	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 2	
Tooth infection			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal abscess			
subjects affected / exposed	4 / 3658 (0.11%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinobronchitis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection fungal			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess limb			
subjects affected / exposed	5 / 3658 (0.14%)	9 / 3683 (0.24%)	
occurrences causally related to treatment / all	0 / 5	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess soft tissue			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal bacteraemia			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary sepsis			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis viral			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronavirus infection			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile infection			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia urinary tract infection			

subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Perirectal abscess			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis bacterial			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess neck			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial sepsis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection bacterial			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stenotrophomonas sepsis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile infection			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia bacteraemia			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal sepsis			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal infection			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Catheter site infection			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infective exacerbation of chronic obstructive airways disease			
subjects affected / exposed	3 / 3658 (0.08%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periorbital cellulitis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infective tenosynovitis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal sepsis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal infection			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute hepatitis B			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Intervertebral discitis			
subjects affected / exposed	2 / 3658 (0.05%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic foot infection			
subjects affected / exposed	5 / 3658 (0.14%)	7 / 3683 (0.19%)	
occurrences causally related to treatment / all	0 / 6	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial infection			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia bacterial			
subjects affected / exposed	7 / 3658 (0.19%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 7	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis infective			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Genitourinary tract infection			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheobronchitis viral			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis bacterial			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Soft tissue infection			
subjects affected / exposed	3 / 3658 (0.08%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection			
subjects affected / exposed	4 / 3658 (0.11%)	6 / 3683 (0.16%)	
occurrences causally related to treatment / all	0 / 4	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis infective			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related infection			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis externa bacterial			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis bacterial			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis bacterial			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Lymphadenitis bacterial			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection bacterial			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural infection			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis norovirus			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Emphysematous pyelonephritis			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal viral infection			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infective exacerbation of bronchiectasis			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infectious pleural effusion			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster meningoencephalitis			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medical device site infection			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal sepsis			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal cord abscess			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Necrotising soft tissue infection			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected bite			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular device infection			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine infection			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular graft infection			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
COVID-19			
subjects affected / exposed	22 / 3658 (0.60%)	17 / 3683 (0.46%)	
occurrences causally related to treatment / all	0 / 22	0 / 17	
deaths causally related to treatment / all	0 / 9	0 / 5	
COVID-19 pneumonia			
subjects affected / exposed	11 / 3658 (0.30%)	9 / 3683 (0.24%)	
occurrences causally related to treatment / all	0 / 11	0 / 9	
deaths causally related to treatment / all	0 / 1	0 / 2	
Metabolism and nutrition disorders			
Cachexia			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			
subjects affected / exposed	10 / 3658 (0.27%)	8 / 3683 (0.22%)	
occurrences causally related to treatment / all	0 / 10	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus			
subjects affected / exposed	25 / 3658 (0.68%)	20 / 3683 (0.54%)	
occurrences causally related to treatment / all	0 / 31	0 / 24	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus inadequate control			

subjects affected / exposed	17 / 3658 (0.46%)	27 / 3683 (0.73%)	
occurrences causally related to treatment / all	0 / 20	0 / 34	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic ketoacidosis			
subjects affected / exposed	8 / 3658 (0.22%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 8	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrolyte imbalance			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fluid overload			
subjects affected / exposed	2 / 3658 (0.05%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gout			
subjects affected / exposed	2 / 3658 (0.05%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercalcaemia			
subjects affected / exposed	0 / 3658 (0.00%)	3 / 3683 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			
subjects affected / exposed	11 / 3658 (0.30%)	23 / 3683 (0.62%)	
occurrences causally related to treatment / all	0 / 11	0 / 24	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkalaemia			
subjects affected / exposed	4 / 3658 (0.11%)	23 / 3683 (0.62%)	
occurrences causally related to treatment / all	4 / 6	15 / 25	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypocalcaemia			

subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemia			
subjects affected / exposed	28 / 3658 (0.77%)	17 / 3683 (0.46%)	
occurrences causally related to treatment / all	0 / 31	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemia			
subjects affected / exposed	6 / 3658 (0.16%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	1 / 7	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypomagnesaemia			
subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	7 / 3658 (0.19%)	6 / 3683 (0.16%)	
occurrences causally related to treatment / all	3 / 9	2 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypovolaemia			
subjects affected / exposed	0 / 3658 (0.00%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic acidosis			
subjects affected / exposed	1 / 3658 (0.03%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obesity			
subjects affected / exposed	3 / 3658 (0.08%)	4 / 3683 (0.11%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic syndrome			

subjects affected / exposed	0 / 3658 (0.00%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic disorder			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic complication			
subjects affected / exposed	2 / 3658 (0.05%)	1 / 3683 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mineral metabolism disorder			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemic hyperosmolar nonketotic syndrome			
subjects affected / exposed	3 / 3658 (0.08%)	2 / 3683 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periarthritis calcarea			
subjects affected / exposed	1 / 3658 (0.03%)	0 / 3683 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Type 2 diabetes mellitus			
subjects affected / exposed	25 / 3658 (0.68%)	33 / 3683 (0.90%)	
occurrences causally related to treatment / all	0 / 33	0 / 45	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic metabolic decompensation			
subjects affected / exposed	13 / 3658 (0.36%)	18 / 3683 (0.49%)	
occurrences causally related to treatment / all	0 / 16	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Placebo	Finerenone	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1717 / 3658 (46.94%)	1797 / 3683 (48.79%)	
Vascular disorders			
Hypertension			
subjects affected / exposed	296 / 3658 (8.09%)	199 / 3683 (5.40%)	
occurrences (all)	347	241	
Nervous system disorders			
Dizziness			
subjects affected / exposed	166 / 3658 (4.54%)	190 / 3683 (5.16%)	
occurrences (all)	184	218	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	199 / 3658 (5.44%)	210 / 3683 (5.70%)	
occurrences (all)	215	227	
General disorders and administration site conditions			
Oedema peripheral			
subjects affected / exposed	278 / 3658 (7.60%)	197 / 3683 (5.35%)	
occurrences (all)	343	227	
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	171 / 3658 (4.67%)	185 / 3683 (5.02%)	
occurrences (all)	192	213	
Diarrhoea			
subjects affected / exposed	220 / 3658 (6.01%)	235 / 3683 (6.38%)	
occurrences (all)	271	283	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	260 / 3658 (7.11%)	296 / 3683 (8.04%)	
occurrences (all)	337	379	
Back pain			
subjects affected / exposed	252 / 3658 (6.89%)	260 / 3683 (7.06%)	
occurrences (all)	287	288	
Infections and infestations			

Bronchitis			
subjects affected / exposed	176 / 3658 (4.81%)	191 / 3683 (5.19%)	
occurrences (all)	214	238	
Nasopharyngitis			
subjects affected / exposed	327 / 3658 (8.94%)	318 / 3683 (8.63%)	
occurrences (all)	497	537	
Upper respiratory tract infection			
subjects affected / exposed	203 / 3658 (5.55%)	225 / 3683 (6.11%)	
occurrences (all)	310	351	
Urinary tract infection			
subjects affected / exposed	220 / 3658 (6.01%)	246 / 3683 (6.68%)	
occurrences (all)	313	335	
Metabolism and nutrition disorders			
Hyperkalaemia			
subjects affected / exposed	159 / 3658 (4.35%)	322 / 3683 (8.74%)	
occurrences (all)	219	470	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
02 May 2017	The major modifications specified in Amendment 3 were an increase of study duration and site numbers to account for lower than expected recruitment rate, amended re-screening rules, a modification of an exclusion criterion to allow randomization of subjects with a recent CV disease episode, and the addition of the definition of the endpoint "kidney failure".
12 March 2019	The main modification due to Amendment 4 was to allow performing the post-treatment Visit as a telephone contact, to specify baseline values for subjects who did not immediately start with study drug treatment, to increase the time window after last study drug administration from 3 to 30 days for on-treatment analyses to better reflect the more protracted nature of the development and diagnosis of clinical outcome events of interest in relation to treatment exposure, and to specify the definition of treatment emergent AEs and interruptions of study treatment.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

None.

Notes:

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/31665733>

<http://www.ncbi.nlm.nih.gov/pubmed/34449181>